High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH
The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Background The changes in nonalcoholic fatty liver disease (NAFLD) range over a wide spectrum, extending from steatosis to steatohepatitis (NASH). However, it has remained difficult to differentiate between NASH and nonprogressive NAFLD by clinical examination. We investigated the interrelationships between serum high-sensitivity C-reactive protein (hs-CRP) and the pathogenesis and progression of NASH.Methods Hs-CRP was measured in 100 patients with histologically verified NAFLD (29 with steatosis and 71 with NASH), and a real-time reverse transcriptase-polymerase chain reaction (RT-PCR) analysis was performed to measure the intrahepatic mRNA expressions of CRP and interleukin (IL)-6.Results The results of a multiple regression analysis revealed that in comparison with cases of steatosis, hs-CRP was significantly elevated (P = 0.0048) in cases of NASH. Furthermore, among patients with NASH, hs-CRP was significantly elevated in those with advanced fibrosis compared with that in those with mild fibrosis (P = 0.0384), even after adjustment for age, sex, presence of diabetes, body mass index, visceral fat area, subcutaneous fat area, homeostasis model assessment for insulin resistance, high-density lipoprotein cholesterol, triglyceride, and low-density lipoprotein cholesterol. The results of the RT-PCR analysis showed that intrahepatic mRNA expression of CRP, but not IL-6, was increased in patients with NASH compared with those with steatosis (P = 0.0228).Conclusions This is the first report to demonstrate consistent and profound elevation of hs-CRP in cases of NASH compared with in cases of simple nonprogressive steatosis. Our results suggest that hs-CRP may be a clinical feature that not only distinguishes NASH from simple nonprogressive steatosis but also indicates the severity of hepatic fibrosis in cases of NASH.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“CRP is predictive of NASH in patients with NAFLD and is related to the presence and severity of liver fibrosis [133].”
From GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives (2023) · cites this paper as [133]
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Ridker, P. M., Hennekens, C. H., Buring, J. E., & Rifai, N. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003233421202 · Cited by 5,850
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., & Hennekens, C. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361401 · Cited by 5,504
Nonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
Ridker, P. M., Rifai, N., Rose, L., Buring, J. E., & Cook, N. R. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021993 · Cited by 3,604
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Ludwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Research works printed but not linked: 4
- JM Hui, 2004, Hepatology, 40, 46
- T Ono, 1999, J Jpn Diabetes Soc, 42, 1005
- JM Hui, 2003, Hepatology, 38, 420
- H Baumann, 1990, Mol Biol Med, 7, 147
Cited by
Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease
Targher, G., Day, C. P., & Bonora, E. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0912063 · Cited by 1,907
The intestinal microbiota fuelling metabolic inflammation
Tilg, H., Zmora, N., Adolph, T. E., & Elinav, E. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0198-4 · Cited by 1,089
Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease
Lebeaupin, C., Vallée, D., Hazari, Y., Hetz, C., Chevet, E., & Bailly-Maitre, B. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.06.008 · Cited by 944
Inflammatory mechanisms in the regulation of insulin resistance
Tilg, H., & Moschen, A. R. (2008) · Molecular Medicine · doi:10.2119/2007-00119.tilg · Cited by 779
“C-reactive protein (CRP), the most important human acute-phase protein, correlates with states of IR (96).”
BackgroundRehman, K., & Akash, M. S. H. (2016) · Journal of Biomedical Science · doi:10.1186/s12929-016-0303-y · Cited by 671
“CRP has been considred as one of the most important human acute phase protein that correlates with development of IR [58, 59].”
BackgroundFrancque, S. M., van der Graaff, D., & Kwanten, W. J. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.04.005 · Cited by 556
Vuppalanchi, R., & Chalasani, N. (2009) · Hepatology · doi:10.1002/hep.22603 · Cited by 563
Vajro, P., Lenta, S., Socha, P., Dhawan, A., McKiernan, P., Baumann, U., Durmaz, O., Lacaille, F., McLin, V., & Nobili, V. (2012) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0b013e318252a13f · Cited by 528
“been reported as a potential marker of severity of fibrosis in lt NASH (98).”
BackgroundNon alcoholic fatty liver disease and metabolic syndrome.
Paschos, P., & Paletas, K. (2009) · PubMed Central · Cited by 718
Causes and Metabolic Consequences of Fatty Liver
Stefan, N., Kantartzis, K., & Häring, H.-U. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0009 · Cited by 532
Insulin resistance, inflammation, and non-alcoholic fatty liver disease
Tilg, H., & Moschen, A. R. (2008) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2008.08.005 · Cited by 473
Kwok, R., Tse, Y. ‐., Wong, G. L. ‐., Ha, Y., Lee, A. U., Ngu, M. C., Chan, H. L. ‐., & Wong, V. W. ‐. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12569 · Cited by 405
“83.(51) However, the results were not reproduced by others.”
ResultTargher, G., Marra, F., & Marchesini, G. (2008) · Diabetologia · doi:10.1007/s00125-008-1135-4 · Cited by 378
“CRP C-reactive protein CVD cardiovascular disease HOMA-IR homeostasis model assessment of insulin resistance IMT intima–media thickness JNK c-Jun N-terminal kinase NAFLD non-alcoholic fatty liver disease NASH non-alcoholic steatohepatitis NF-κB nuclear factor-κB PAI-1 plasminogen activator inhibitor-1”
BackgroundInfluentialAssociation of Inflammatory Cytokines With Non-Alcoholic Fatty Liver Disease
Duan, Y., Pan, X., Luo, J., Xiao, X., Li, J., Bestman, P. L., & Luo, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.880298 · Cited by 358
“Yoneda (2007) (65) Cohort 71 29 NASH CRP 12 Yu (2018) (66) Cross-sectional 7592 12797 NAFLD CRP 9”
Diagnosis and Therapy of Nonalcoholic Steatohepatitis
Torres, D. M., & Harrison, S. A. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.02.077 · Cited by 354
Stojsavljević, S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i48.18070 · Cited by 325
Dowman, J. K., Tomlinson, J. W., & Newsome, P. N. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04556.x · Cited by 312
You, T., Arsenis, N. C., Disanzo, B. L., & LaMonte, M. J. (2013) · Sports Medicine · doi:10.1007/s40279-013-0023-3 · Cited by 285
“Chronic inflammation is a shared characteristic in the pathophysiology of several diseases including cardiovascular diseases [1–4], type 2 diabetes mellitus [5, 6], the metabolic syndrome [6], periodontal disease [20], osteoporosis [21], sarcopenia [22], certain cancers [23], arthritis [24], chronic lung disease [25],…”
BackgroundA concise review of non-alcoholic fatty liver disease
Than, N. N., & Newsome, P. N. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.01.001 · Cited by 287
“A observational study showed that high CRP levels are higher in biopsy proven NASH compared to SS although CRP levels do not reflect the degree between inflammation and fibrosis [71].”
BackgroundNevola, R., Epifani, R., Imbriani, S., Tortorella, G., Aprea, C., Galiero, R., Rinaldi, L., Marfella, R., & Sasso, F. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021703 · Cited by 286
“In addition to T2DM and increased cardiovascular risk [132], CRP is predictive of NASH in patients with NAFLD and is related to the presence and severity of liver fibrosis [133].”
BackgroundMetabolic disturbances in non-alcoholic fatty liver disease
Byrne, C. D., Olufadi, R., Bruce, K. D., Cagampang, F. R., & Ahmed, M. H. (2009) · Clinical Science · doi:10.1042/cs20080253 · Cited by 258
Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease
Obika, M., & Noguchi, H. (2012) · Experimental Diabetes Research · doi:10.1155/2012/145754 · Cited by 242
“There was a significant increase in high-sensitivity CRP levels in NASH patients compared with controls in some studies [51, 52], and no significant difference in another [53].”
ResultTargher, G., Bertolini, L., Rodella, S., Lippi, G., Zoppini, G., & Chonchol, M. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05050610 · Cited by 233
NASH Predicts Plasma Inflammatory Biomarkers Independently of Visceral Fat in Men
Targher, G., Bertolini, L., Rodella, S., Lippi, G., Franchini, M., Zoppini, G., Muggeo, M., & Day, C. P. (2008) · Obesity · doi:10.1038/oby.2008.64 · Cited by 214
Non-alcoholic fatty liver disease: What the clinician needs to know
Machado, M. V. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i36.12956 · Cited by 204
Association of C-reactive protein with type 2 diabetes: prospective analysis and meta-analysis
Lee, C. C., Adler, A. I., Sandhu, M. S., Sharp, S. J., Forouhi, N. G., Erqou, S., Luben, R., Bingham, S., Khaw, K. T., & Wareham, N. J. (2009) · Diabetologia · doi:10.1007/s00125-009-1338-3 · Cited by 202
“CRP originates in the liver and is increased in people with liver steatosis [ 32 ], suggesting a link between chronic inflammation and non-alcoholic fattyliver disease.”
BackgroundMouliou, D. S. (2023) · Diseases · doi:10.3390/diseases11040132 · Cited by 160
Nonalcoholic fatty liver disease: A comprehensive review of a growing epidemic
Hassan, K. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i34.12082 · Cited by 186
The pentraxins PTX3 and SAP in innate immunity, regulation of inflammation and tissue remodelling
Bottazzi, B., Inforzato, A., Messa, M., Barbagallo, M., Magrini, E., Garlanda, C., & Mantovani, A. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.02.029 · Cited by 185
“NASH compared to non-NASH, and levels were associated with the degree of fibrosis [91-93].”
BackgroundDuval, C., Thissen, U., Keshtkar, S., Accart, B., Stienstra, R., Boekschoten, M. V., Roskams, T., Kersten, S., & Müller, M. (2010) · Diabetes · doi:10.2337/db10-0224 · Cited by 187
“In one study, high-sensitivity CRP was significantly elevated in patients with NASH compared with that in patients with only steatosis (29).”
Newsome, P., Francque, S., Harrison, S., Ratziu, V., Van Gaal, L., Calanna, S., Hansen, M., Linder, M., & Sanyal, A. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15316 · Cited by 186
Nonalcoholic Fatty Liver Disease Pandemic Fuels the Upsurge in Cardiovascular Diseases
Cai, J., Zhang, X.-J., Ji, Y.-X., Zhang, P., She, Z.-G., & Li, H. (2020) · Circulation Research · doi:10.1161/circresaha.119.316337 · Cited by 177
Ndumele, C. E., Nasir, K., Conceiçao, R. D., Carvalho, J. A. M., Blumenthal, R. S., & Santos, R. D. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.228262 · Cited by 179
Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: Is there a link?
Targher, G., Chonchol, M., Zoppini, G., Abaterusso, C., & Bonora, E. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.11.007 · Cited by 171
Nonalcoholic fatty liver disease: Diagnostic biomarkers
Hadizadeh, F., Faghihimani, E., & Adibi, P. (2017) · World Journal of Gastrointestinal Pathophysiology · doi:10.4291/wjgp.v8.i2.11 · Cited by 168
Increased risk of cardiovascular disease and chronic kidney disease in NAFLD
Bonora, E., & Targher, G. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.79 · Cited by 169
Targher, G., Bertolini, L., Chonchol, M., Rodella, S., Zoppini, G., Lippi, G., Zenari, L., & Bonora, E. (2010) · Diabetologia · doi:10.1007/s00125-010-1720-1 · Cited by 158
Gambino, R., Musso, G., & Cassader, M. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.3058 · Cited by 147
Baranova, A., Tran, T. P., Birerdinc, A., & Younossi, Z. M. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04579.x · Cited by 146
Targher, G., Chonchol, M., Miele, L., Zoppini, G., Pichiri, I., & Muggeo, M. (2009) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0029-1222606 · Cited by 145
“, CRP, fibrinogen, PAI-1, and other proinflammatory cytokines).(3,5,6,21,22,26,27,34) In addition, NAFLD/NASH may cause further increases in wholebody insulin resistance and promote atherogenic dyslipidemia (with a characteristic overproduction of triglyceride- and cholesterol-rich remnant particles),(5,6) thus in tur…”
BackgroundEfficacy of ezetimibe for the treatment of non‐alcoholic steatohepatitis: An open‐label, pilot study
Yoneda, M., Fujita, K., Nozaki, Y., Endo, H., Takahashi, H., Hosono, K., Suzuki, K., Mawatari, H., Kirikoshi, H., Inamori, M., et al. (2010) · Hepatology Research · doi:10.1111/j.1872-034x.2010.00644.x · Cited by 138
Self-citationStatins in liver disease: A molehill, an iceberg, or neither?†
Argo, C. K., Loria, P., Caldwell, S. H., & Lonardo, A. (2008) · Hepatology · doi:10.1002/hep.22402 · Cited by 128
Sookoian, S. C., Castaño, G. O., Burgueño, A. L., Rosselli, M. S., Gianotti, T. F., Mallardi, P., Martino, J. S., & Pirola, C. J. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.10.011 · Cited by 136
Tam, C. S., Viardot, A., Clément, K., Tordjman, J., Tonks, K., Greenfield, J. R., Campbell, L. V., Samocha-Bonet, D., & Heilbronn, L. K. (2010) · Diabetes · doi:10.2337/db10-0162 · Cited by 126
Lonardo, A., Sookoian, S., Chonchol, M., Loria, P., & Targher, G. (2013) · Current Pharmaceutical Design · doi:10.2174/1381612811319290003 · Cited by 115
“…CSF2, IL1A, IL3, IL4, LIF and MMP1 in NASH (case-control study) Wieckowska, 2008 (127) Increased hepatic expression of IL-6 (case-control study) Yoneda, 2007 (128) Increased hepatic expression of CRP (case-control study) Thuy, 2008 (129) Increased hepatic expression of PAI-1 (case-control…”
Nonalcoholic fatty liver disease and cardiovascular risk
Misra, V. L., Khashab, M., & Chalasani, N. (2009) · Current Gastroenterology Reports · doi:10.1007/s11894-009-0008-4 · Cited by 122
“…Senturk et al. 2008[53] Framingham Risk Score Ioannou et al. 2006[13] Carotid intima media thickness Targher et al. 2004[17] Brea et al. 2005[16] Volzke et al. 2005[19] Pacifico et al. 2008[15] hsCRP Yoneda et al. 2007[54] Curr Gastroenterol Rep. Author manuscript; available in PMC 2009 August 26.”
BackgroundZimmermann, E., Anty, R., Tordjman, J., Verrijken, A., Gual, P., Tran, A., Iannelli, A., Gugenheim, J., Bédossa, P., Francque, S., et al. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.12.017 · Cited by 126
Banerjee, A., Mukherjee, S., & Maji, B. K. (2021) · Toxicology Reports · doi:10.1016/j.toxrep.2021.04.009 · Cited by 138
Review article: diagnosis and treatment of non‐alcoholic fatty liver disease
OH, M. K., Winn, J., & Poordad, F. F. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03752.x · Cited by 137
The Metabolic Syndrome as a Concept of Adipose Tissue Disease
Oda, E. (2008) · Hypertension Research · doi:10.1291/hypres.31.1283 · Cited by 131
Mencarelli, A., Cipriani, S., Renga, B., Bruno, A., D'Amore, C., Distrutti, E., & Fiorucci, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045425 · Cited by 116
Kadayıfçı, A., Tan, V. S., Ursell, P. C., Merriman, R. B., & Bass, N. M. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.05.024 · Cited by 122
“However, profound elevation of high-sensitivity CRP has been reported in cases of NASH compared to simple steatosis in another recent study [29].”
BackgroundFricker, Z. P., Pedley, A., Massaro, J. M., Vasan, R. S., Hoffmann, U., Benjamin, E. J., & Long, M. T. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.11.037 · Cited by 110
“In several small studies, participants with NAFLD and insulin resistance14,15 or the metabolic syndrome16 had higher measures of systemic inflammation compared with those without NAFLD.”
InfluentialGenome‐Wide Association Study of NAFLD Using Electronic Health Records
Fairfield, C. J., Drake, T. M., Pius, R., Bretherick, A. D., Campbell, A., Clark, D. W., Fallowfield, J. A., Hayward, C., Henderson, N. C., Joshi, P. K., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.1805 · Cited by 97
Role of FXR in Liver Inflammation During Nonalcoholic Steatohepatitis
Armstrong, L. E., & Guo, G. L. (2017) · Current Pharmacology Reports · doi:10.1007/s40495-017-0085-2 · Cited by 90
Serum interleukin‐6 associated with hepatocellular carcinoma risk: A nested case–control study
Ohishi, W., COLOGNE, J. B., Fujiwara, S., Suzuki, G., Hayashi, T., Niwa, Y., Akahoshi, M., Ueda, K., Tsuge, M., & Chayama, K. (2013) · International Journal of Cancer · doi:10.1002/ijc.28337 · Cited by 104
“This result is consistent with published findings that background liver disease of non-B, non-C HCC may be partially caused by NASH or steatohepatitis.(40,41) Several studies have reported that higher serum IL-6 level precedes the development of HCC in female chronic hepatitis C patients or chronic hepatitis B patient…”
BackgroundResultNoninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD
Pearce, S. G., Thosani, N. C., & Pan, J.-J. (2013) · Biomarker Research · doi:10.1186/2050-7771-1-7 · Cited by 97
“reported that marked elevation of serum hyaluronic acid (HA) and type IV collagen 7S domain, both ECM components, occurred in NASH patients with advanced fibrosis compared to those with mild fibrosis [24].”
BackgroundInfluentialNASH and atherosclerosis are two aspects of a shared disease: Central role for macrophages
Bieghs, V., Rensen, P. C. N., Hofker, M. H., & Shiri‐Sverdlov, R. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.08.041 · Cited by 108
“It has been shown that levels of fibrinogen, plasminogen activator inhibitor-1 (PAI-1) and C-reactive protein (CRP), all of which are CVD risk factors, are increased in NASH patients and correlate with histological severity, independently of the traditional risk factors and components of the metabolic syndrome [17–20].”
BackgroundSong, L., Qu, D. C., Zhang, Q., Jiang, J., Zhou, H., Jiang, R., Li, Y., Zhang, Y., & Yan, H. (2017) · Scientific Reports · doi:10.1038/srep41604 · Cited by 101
Plasma Pentraxin3 is a Novel Marker for Nonalcoholic Steatohepatitis (NASH)
Yoneda, M., Uchiyama, T., Kato, S., Endo, H., Fujita, K., Yoneda, K., Mawatari, H., Iida, H., Takahashi, H., Kirikoshi, H., et al. (2008) · BMC Gastroenterology · doi:10.1186/1471-230x-8-53 · Cited by 94
“Some recent reports have suggested that hs-CRP may be an independent risk factor for progression of NAFLD [35-37], and we have reported the clinical usefulness of the measurement of hs-CRP for diagnosis of NASH [10].”
BackgroundSelf-citationHribal, M. L., Procopio, T., Petta, S., Sciacqua, A., Grimaudo, S., Pipitone, R. M., Perticone, F., & Sesti, G. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3290 · Cited by 88
Yoneda, M., Nozaki, Y., Endo, H., Mawatari, H., Iida, H., Fujita, K., Yoneda, K., Takahashi, H., Kirikoshi, H., Inamori, M., et al. (2009) · Digestive Diseases and Sciences · doi:10.1007/s10620-009-0771-y · Cited by 89
Self-citationPaquissi, F. C. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00490 · Cited by 95
“Additionally, an elevated CRP is a predictor of disease progression and severity, as shown that hs-CRP was significantly higher in cases of NASH than in simple steatosis (19, 45); furthermore, among patients with NASH, hs-CRP was significantly elevated in those with advanced fibrosis compared with those with mild, eve…”
BackgroundOda, K., Uto, H., Mawatari, S., & Ido, A. (2015) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-014-0548-5 · Cited by 90
Nonalcoholic fatty liver disease: a challenge for pediatricians
Widhalm, K., & Ghods, E. (2010) · International Journal of Obesity · doi:10.1038/ijo.2010.185 · Cited by 91
Li, L., Huang, Q., Yang, L., Zhang, R., Gao, L., Han, X., Ji, L., & Zou, X. (2022) · Nutrients · doi:10.3390/nu14061224 · Cited by 95
“NAFLD, non-alcoholic fatty liver disease; FLI, Fatty Liver Index; USFLI, U.S. Fatty Liver Index; NFS, NAFLD fibrosis score; FIB-4, Fibrosis-4 index; APRI, AST-to-platelet ratio index; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; TG, triglyceride; HDL, high-density lipoprotein chol…”
BackgroundInfluentialTarantino, G., Conca, P., Riccio, A., Tarantino, M., Di Minno, M. N., Chianese, D., Pasanisi, F., Contaldo, F., Scopacasa, F., & Capone, D. (2008) · Journal of Translational Medicine · doi:10.1186/1479-5876-6-72 · Cited by 83
“Further, we failed to confirm the crucial role of CRP in differentiating FL from NASH even though NASH patients revealed the highest concentrations [15].”
Noninvasive investigations for non alcoholic fatty liver disease and liver fibrosis
Fierbinteanu-Braticevici, C. G., Dina, I., Petrişor, A., Tribuș, L., Negreanu, L., & Cârstoiu, C. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i38.4784 · Cited by 92
Nishikawa, H., Enomoto, H., Iwata, Y., Hasegawa, K., Nakano, C., Takata, R., Nishimura, T., Yoh, K., Aizawa, N., Sakai, Y., et al. (2015) · Hepatology Research · doi:10.1111/hepr.12596 · Cited by 85
Tarantino, G., Colicchio, P., Conca, P., Finelli, C., Minno, M. N. D. D., Tarantino, M., Capone, D., & Pasanisi, F. (2009) · Journal of Inflammation · doi:10.1186/1476-9255-6-6 · Cited by 80
“Furthermore, some Authorities have proposed CRP levels as reliable tool to help diagnose NASH and weigh NASH staging [13].”
MethodNigam, P., Bhatt, S. P., Misra, A., Vaidya, M., Dasgupta, J., & Chadha, D. S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0049286 · Cited by 87
Retinol and α-Tocopherol in Morbid Obesity and Nonalcoholic Fatty Liver Disease
Botella-Carretero, J. I., Balsa, J. A., Vázquez, C., Peromingo, R., Díaz-Enriquez, M., & Escobar-Morreale, H. F. (2008) · Obesity Surgery · doi:10.1007/s11695-008-9686-5 · Cited by 84
“Insulin resistance and oxidative stress play an important role in nonalcoholic fatty liver development and progression [36], but chronic inflammation has also been implicated in its pathogenesis and severity [ 37 ].”
BackgroundOverview and developments in noninvasive diagnosis of nonalcoholic fatty liver disease
Baršić, N., Lerotić, I., Smirčić-Duvnjak, L., Tomašić, V., & Duvnjak, M. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i30.3945 · Cited by 84
Paul, J. (2020) · Egyptian Liver Journal · doi:10.1186/s43066-020-00043-x · Cited by 79
“in their study did not find any increase in expression of IL-6 in patients with steatohepatitis as compared to patients with simple hepatic steatosis [53].”
ResultSerum procalcitonin and CRP levels in non-alcoholic fatty liver disease: a case control study
Oruç, N., Özütemız, Ö., Yüce, G., Akarca, U. S., Ersöz, G., Günşar, F., & Batur, Y. (2009) · BMC Gastroenterology · doi:10.1186/1471-230x-9-16 · Cited by 77
“There were limited number of studies implying that serum CRP was elevated in NAFLD [ 16- 18 ].”
Nonalcoholic Fatty Liver Disease and the Coronary Artery Disease
Treeprasertsuk, S., López-Jiménez, F. A., & Lindor, K. D. (2010) · Digestive Diseases and Sciences · doi:10.1007/s10620-010-1241-2 · Cited by 76
“However, there was a contradicting result showing that hs-CRP was significantly elevated in patients with advanced liver fibrosis compared with those who had mild fibrosis after adjusted for age, sex, presence of diabetes, BMI, visceral fat, HOMA, HDL-cholesterol, triglyceride, and LDL-cholesterol [56].”
ResultForoughi, M., Maghsoudi, Z., Khayyatzadeh, S., Ghiasvand, R., Askari, G., & Iraj, B. (2016) · Advanced Biomedical Research · doi:10.4103/2277-9175.176368 · Cited by 67
“It is well-established that reactive oxygen species (ROS)-induced activation pathways rely primarily on the inhibitor of κB-kinase complex activation, a process that may also be triggered by the pro-inflammatory cytokines TNF-α and interleukin-1β (IL-1β) as well as by lipopolysaccharide,[25,26] through different signa…”
BackgroundInflammatory Diseases and Vitamin E—What Do We Know and Where Do We Go?
Wallert, M., Börmel, L., & Lorkowski, S. (2020) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202000097 · Cited by 74
Davidson, M. D., Kukla, D. A., & Khetani, S. R. (2017) · Integrative Biology · doi:10.1039/c7ib00027h · Cited by 66
Mr, A., Yaccha, M., Malik, M. A., Rabbani, M. U., Ahmad, I., Isalm, N., & Abdali, N. (2014) · Indian Heart Journal · doi:10.1016/j.ihj.2014.08.006 · Cited by 71
Chiang, C.-H., Huang, C., Chan, W., Chen, J., & Leu, H. (2010) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2010.09.003 · Cited by 65
“uptake into macrophages [40,41].”
Banerjee, A., Das, D., Paul, R., Roy, S., Das, U. B., Saha, S., Dey, S., Adhikary, A., Mukherjee, S., & Maji, B. K. (2020) · Scientific Reports · doi:10.1038/s41598-020-72076-6 · Cited by 65
The long pentraxin PTX 3: A prototypical sensor of tissue injury and a regulator of homeostasis
Erreni, M., Manfredi, A. A., Garlanda, C., Mantovani, A., & Rovere, P. Q. (2017) · Immunological Reviews · doi:10.1111/imr.12570 · Cited by 63
Bell, L. N., Lee, L., Saxena, R., Bemis, K. G., Wang, M., Theodorakis, J. L., Vuppalanchi, R., Alloosh, M., Sturek, M. S., & Chalasani, N. (2010) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00485.2009 · Cited by 59
Porter, S. A., Pedley, A., Massaro, J. M., Vasan, R. S., Hoffmann, U., & Fox, C. S. (2012) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.112.300075 · Cited by 59
“In addition, the liver is the site of production for biomarkers of inflammation and endothelial dysfunction, including C-reactive protein, fibrinogen, and plasminogen activator inhibitor-1, all of which are elevated in fatty liver disease and which are considered biomarkers of CVD risk.(15,31) Our findings showed a gr…”
BackgroundTakino, J.-I., Kobayashi, Y., & Takeuchi, M. (2010) · Journal of Gastroenterology · doi:10.1007/s00535-009-0193-9 · Cited by 59
“Recent studies have shown that the concentration of high-sensitivity CRP is elevated in the plasma of patients with NASH compared to that in patients with simple steatosis and that in healthy subjects [39, 40].”
BackgroundHaufe, S., Engeli, S., Budziarek, P., Utz, W., Schulz‐Menger, J., Hermsdorf, M., Wiesner, S., Otto, C., Haas, V. K., de Greiff, A., et al. (2010) · Diabetes · doi:10.2337/db09-1200 · Cited by 62
“hs-CRP is elevated in liver disease and predicts the incidence of type 2 diabetes in humans (43,44).”
Non-alcoholic fatty liver disease is associated with progression of arterial stiffness
Li, N., Zhang, G.-W., Zhang, J.-R., Jin, D., Li, Y., Liu, T., & Wang, R.-T. (2014) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2014.10.002 · Cited by 54
“Furthermore, C-reactive protein, an inflammatory marker, correlates with the histologic severity of NAFLD [22].”
Miller, M. H., Ferguson, M. A. J., & Dillon, J. F. (2011) · Liver International · doi:10.1111/j.1478-3231.2011.02451.x · Cited by 60
“(43) measured serum ferritin in 100 patients with NAFLD (29 SS and 71 NASH), finding significantly higher levels in the NASH cohort.”
BackgroundFierbinteanu-Braticevici, C. G., Băicuş, C., Tribus, L. C., & Papacocea, R. I. (2011) · PubMed · Cited by 65
Verhaegh, P. L. M., Bavalia, R., Winkens, B., Masclee, A., Jonkers, D. M. A. E., & Koek, G. H. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.08.024 · Cited by 58
Meyer, M., Schwärzler, J., Jukic, A., & Tilg, H. (2024) · Biomolecules · doi:10.3390/biom14040476 · Cited by 50
“High-sensitivity C-reactive protein, an acute phase protein which is up-regulated by proinflammatory cytokines, is significantly increased in patients with MASH, and the levels were especially pronounced in patients with advanced fibrosis [12].”
BackgroundChu, K., Cadar, D., Iob, E., & Frank, P. (2022) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2022.11.016 · Cited by 49
“This supports earlier findings showing that in individuals with obesity, adipose tissue dysfunction is a key factor contributing to low-grade inflammation, as indicated by elevated concentrations of CRP and IL-6 (Yudkin et al., 1999).”
BackgroundResultInfluentialRomain, C., Gaillet, S., Carillon, J., Vidé, J., Ramos, J., Izard, J., Cristol, J., & Rouanet, J. (2012) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf303549t · Cited by 49
Lambrecht, J., & Tacke, F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.634409 · Cited by 43
“This latter finding also correlated to the elevated CRP mRNA levels that were found in the liver tissue of NASH patients (40).”
BackgroundResultInfluentialNishikawa, H., Enomoto, H., Iwata, Y., Hasegawa, K., Nakano, C., Takata, R., Nishimura, T., Yoh, K., Aizawa, N., Sakai, Y., et al. (2016) · Hepatology Research · doi:10.1111/hepr.12595 · Cited by 45
NAFLD and Increased Aortic Stiffness: Parallel or Common Physiopathological Mechanisms?
Villela‐Nogueira, C. A., Leite, N. C., Cardoso, C. R. L., & Salles, G. F. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17040460 · Cited by 46
“showed, for the first time, elevated levels of high-sensitivity C-reactive protein (hs-CRP) in patients with biopsy-proven NASH, implying there may be a shared pathway between the severity of liver disease and the levels of hs-CRP, a well-known marker of cardiovascular risk [27].”
BackgroundDemir, M., Lang, S., Nierhoff, D., Drebber, U., Hardt, A., Wedemeyer, I., Schulte, S., Quasdorff, M., Goeser, T., Töx, U., et al. (2013) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3182819a89 · Cited by 42
“All patients, n (%) 130 (79) 27 (16) 8 (5) 165 F0-F2, n (%) 127 (88) 18 (12) 0 145 F3-F4, n (%) 3 (15) 9 (45) 8 (40) 20 Sensitivity, % 85 40 Specificity, % 88 100 PPV, % 49 100”
Tanaka, M., Okada, H., Hashimoto, Y., Kumagai, M., Nishimura, H., Oda, Y., & Fukui, M. (2020) · Liver International · doi:10.1111/liv.14253 · Cited by 45
Obeticholic acid for the treatment of nonalcoholic steatohepatitis
Shah, R. A., & Kowdley, K. V. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2020.1748498 · Cited by 48
“and is associated with severity of liver fibrosis [64].”
Background
Metadata
- Authors
- Yoneda, M., Mawatari, H., Fujita, K., Iida, H., Yonemitsu, K., Kato, S., Takahashi, H., Kirikoshi, H., Inamori, M., Nozaki, Y., Abe, Y., Kubota, K., Saito, S., Iwasaki, T., Terauchi, Y., Togo, S., Maeyama, S., & Nakajima, A.
- Affiliations
- Yokohama City University Hospital (JP)
- Yokohama City University (JP)
- Kitakashiwa Rehabilitation General Hospital (JP)
- ORCID
- Venue
- Journal of Gastroenterology
- Published
- 2007-07-25
- Volume
- 42
- Issue
- 7
- Pages
- 573-582
- ISSN
- 0944-1174 (ISSN-L)
- 1435-5922
- OpenAlex
- W2060798922
- Cited by
- 294
- References
- 50
- Citations by year
- 2026: 7 · 2025: 13 · 2024: 9 · 2023: 16 · 2022: 17 · 2021: 19 · 2020: 15 · 2019: 10 · 2018: 10 · 2017: 17 · 2016: 18 · 2015: 14 · 2014: 14 · 2013: 21 · 2012: 14
- FWCI
- 14.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Journal of Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- high-sensitivity C-reactive protein, nonalcoholic steatohepatitis, non-alcoholic fatty liver disease, hepatic steatosis, liver fibrosis severity, interleukin-6, inflammatory markers, disease progression
- MeSH terms
- Adult, C-Reactive Protein, Fatty Liver, Female, Hepatitis, Humans, Liver, Liver Cirrhosis, Male, Middle Aged, Prospective Studies, RNA, Messenger, Severity of Illness Index, Biomarkers, Interleukin-6, Gene Expression, Logistic Models, Reverse Transcriptase Polymerase Chain Reaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.